ESR1 and neoplasm: In estrogen receptor–positive tumors, Selective Estrogen Receptor Degraders (SERDs) and proteolysis-targeting chimeras (PROTACs) offer new options to disrupt or eliminate proteins that sustain tumor growth [236].